Lundbeck breathes life into stranded molecule to treat new diseases

Drug candidate LU AG06466, which failed as a treatment for Tourette's, is the center of attention in two new phase I trials Lundbeck has launched this summer.
Photo: Lundbeck / PR
Photo: Lundbeck / PR

Lundbeck means business in picking drug candidate LU AG06466 back up again. The Danish pharmaceutical company is testing the drug in three phase I trials. In March 2020, it failed as a treatment for Tourette's syndrome in a phase II trial.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading